isosorbide has been researched along with niacin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Bazou, D; Cantwell, P; Gilmer, JF; Harmon, S; Inkielewicz, I; Jones, M; Ledwidge, M; Medina, C; Radomski, MW; Santos-Martinez, MJ | 1 |
| Cefali, G; Gilmer, JF; Harmon, S; Jones, M; Kerins, DM; Ledwidge, MT; O'Connell, D; Ryan, F | 1 |
3 other study(ies) available for isosorbide and niacin
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.
Topics: Aspirin; Blood Platelets; Cell Communication; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Stability; Flow Cytometry; Humans; Isosorbide; Microscopy, Phase-Contrast; Niacin; Physostigmine; Platelet Aggregation; Prodrugs | 2012 |
In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?
Topics: Animals; Apolipoproteins B; Aspirin; Blood Glucose; Chemistry, Pharmaceutical; Cholesterol, LDL; Cyclooxygenase Inhibitors; Hyperglycemia; Hypolipidemic Agents; Isosorbide; Lipid Metabolism; Lipids; Macaca fascicularis; Models, Biological; Niacin; Postprandial Period; Prodrugs; Prostaglandin D2; Salicylates; Thromboxane B2; Triglycerides | 2012 |